Study #2011-0953
A Phase 1 Trial of Vandetanib (A Multi-Kinase Inhibitor of EGFR, VEGFR and RET inhibitor) in Combination with Everolimus (an mTOR inhibitor) in Advanced Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Everolimus, Vandetanib
Description
This phase I trial studies the side effects and best dose of vandetanib and everolimus when given together in treating patients with cancer that has spread to other places in the body. Vandetanib and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Study phase:
Phase I
Physician name:
Sarina Piha-Paul
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.